High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
In the last week, the United States market has stayed flat, yet it has seen a significant increase of 24% over the past year with earnings forecasted to grow by 19% annually. In this context, identifying stocks that are estimated to be undervalued can offer investors potential opportunities for capitalizing on price discrepancies relative to their fair value.
Over the last 7 days, the United States market has remained flat, yet it is up 24% over the past year with earnings anticipated to grow by 19% annually in the coming years. In this context of robust growth expectations, identifying stocks that are trading below their intrinsic value can present opportunities for investors seeking potential long-term gains.
We recently published Jim Cramer Didn’t Hold Back On SpaceX’s IPO & Discussed These 12 Stocks. Johnson & Johnson (NYSE:JNJ) is one of the stocks discussed by Jim Cramer. Johnson & Johnson (NYSE:JNJ)’s shares are up by 53% over the past year and by 15% year-to-date. Leerink Partners discussed the firm on May 13th as […]
While the market fixates on the STELARA patent cliff, the rest of the business is quietly accelerating. Excluding the legacy drug, Johnson & Johnson (JNJ) grew in double digits for the quarter. The Innovative Medicine segment absorbed a massive 920 basis point headwind from STELARA, yet still posted 7.4% growth. This is not a company treading water, but a portfolio already hitting its next stride.
For investors considering whether Merck at around US$120.76 still offers value or whether most of the upside is already reflected in the price, this article walks through the key checks investors often rely on. With the stock showing returns of 0.4% over 7 days, 7.5% over 30 days, 13.4% year to date and 53.0% over 1 year, many holders are now asking whether the current price fairly reflects the business. Recent headlines around Merck have focused on its position as a major pharmaceuticals...
Healthcare stocks edged lower late Friday afternoon, with the NYSE Healthcare Index and the State St
BMY's growth portfolio now drives more than half of revenues, with strong gains from Reblozyl, Breyanzi and Cobenfy helping offset legacy drug declines.
Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Phibro Animal Health unit drove 74% of fiscal 2025 revenue, fueled by MFA, vaccines and global expansion, helping offset pressure in other businesses.
Merck Animal Health has agreed to acquire TARGAN, a biodevice company focused on poultry solutions. The deal adds automated, technology driven tools aimed at the poultry sector to Merck's animal health offering. This marks a further step for Merck into animal health technologies alongside its human medicines business. Merck (NYSE:MRK) is drawing fresh attention after its animal health unit moved to acquire TARGAN, a poultry focused biodevice developer. With the share price at $120.76 and a...
In the closing of the recent trading day, Merck (MRK) stood at $120.76, denoting a +1.4% move from the preceding trading day.
Gilead Sciences Inc. (NASDAQ:GILD) is one of the top large cap value stocks to buy now. On June 8, Gilead Sciences and Merck announced positive topline results from two Phase 3 clinical trials, ISLEND-1 and ISLEND-2, evaluating their investigational once-weekly oral HIV treatment. The regimen, which combines islatravir and lenacapavir, successfully met its primary efficacy […]
Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.
Merck, Southern Company, Lumentum and Peoples Bancorp of North Carolina are highlighted for growth drivers, performance and key risks.
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Phibro trades near 10x forward earnings vs higher peer multiples as strong Q3 beat, margin gains and 2026 guidance support a modest upside case.
Merck, Southern Company and Lumentum lead Zacks' featured research reports as growth drivers, expansion plans and key risks shape outlooks.
While Pyxis Oncology, Inc. (NASDAQ:PYXS) has gained 54.78% year-to-date, analysts continue to see 293.30% upside, helping it secure a spot on our list of hot biotech stocks under $5 to buy. That analyst conviction is rooted in a busy clinical calendar, with key data readouts from Pyxis Oncology, Inc. (NASDAQ:PYXS)’s lead program expected across the […]
Gilead's HIV franchise gains momentum as Biktarvy and Descovy drive growth, Yeztugo outlook rises, and late-stage pipeline advances.
Merck (NYSE:MRK) announced a partnership with The Hashgraph Group to build digital product traceability tools aligned with new EU transparency and compliance rules. The company is also working with global health authorities to explore use of its existing antiviral pill and vaccine technologies against the emerging Bundibugyo strain Ebola outbreak. Both developments highlight changes in Merck’s approach to supply chain authentication and infectious disease response that had not been covered...
MRK has reclaimed its 50-day SMA while holding above its 200-day trendline, backed by Keytruda growth, pipeline advances and recent deals.
Gilead and Merck report positive phase III results for once-weekly HIV regimen islatravir/lenacapavir, while ending a lung cancer study.
Gilead Sciences (NasdaqGS:GILD) and Merck reported that their once weekly oral HIV regimen, islatravir and lenacapavir, met its primary endpoint in a Phase 3 trial, showing statistically non inferior efficacy to daily standard of care. The companies also stopped a Phase 3 study combining Trodelvy and KEYTRUDA in advanced lung cancer after the treatment did not deliver a statistically significant improvement in progression free survival. These mixed trial outcomes arrive with Gilead Sciences...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.93%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.89%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.17%. June E-mini S&P futures (ESM26 ) are up +0.76%, and June E-mini Nasdaq futures...
Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.
In early June 2026, Gilead Sciences and Merck reported that their investigational once-weekly oral HIV regimen of islatravir/lenacapavir met the primary efficacy endpoint and showed a comparable safety profile to standard daily treatments in two Phase 3 ISLEND trials, and they plan global regulatory filings based on these data. At the same time, Merck and Gilead halted a Phase 3 lung cancer study combining Trodelvy with KEYTRUDA after it failed to show a statistically significant...
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
